ArticleDiscover oncology2025
Single cell analysis reveals cancer associated fibroblast subtypes as prognostic markers and therapeutic targets in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remodeling the Stroma: The Role of ncRNAs in Cancer-Associated Fibroblasts and Therapeutic Implications for Digestive Tumors.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCancer-associated fibroblasts (CAFs) play a pivotal role in Gastric cancer (GC) progression and immune modulation. This study aimed to identify CAF subtypes using single-cell analysis and evaluate their prognostic and therapeutic relevance in GC.
methodsCAF gene sets were derived from 13 single-cell datasets and quantified via ssGSEA in bulk transcriptomic cohorts (TCGA and GEO). Consensus clustering defined CAF-based subtypes. Immune infiltration was evaluated using CIBERSORT, xCell, MCPcounter, and ESTIMATE. Immunotherapy response was predicted using TIDE and ImmuCellAI. Chemotherapeutic sensitivity was assessed via PRISM, CTRP, and GDSC databases. Hub genes were identified by WGCNA, and a prognostic model was constructed and validated in external cohorts and at the single-cell level.
resultsTwo CAF subtypes, FA_H and FA_L, were identified. FA_H was associated with poor prognosis, higher M2 macrophage infiltration, and immunosuppressive pathways, while FA_L correlated with improved survival and stronger predicted response to immune checkpoint inhibitors. Dasatinib was predicted as a potential therapeutic agent specifically for FA_H subtype. A five-gene prognostic model (COL1A2, NDN, SPARC, VCAN, TCEAL7) showed consistent predictive performance across datasets. Functional validation confirmed upregulation of TCEAL7 in CAFs and its role in promoting GC cell invasion.
conclusionSingle-cell-based CAF subtyping defines clinically relevant heterogeneity in GC. The FA_H subtype may serve as both a prognostic biomarker and therapeutic target, particularly for dasatinib-based or immunomodulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.